PH12016501629B1 - Uti fusion proteins - Google Patents

Uti fusion proteins

Info

Publication number
PH12016501629B1
PH12016501629B1 PH1/2016/501629A PH12016501629A PH12016501629B1 PH 12016501629 B1 PH12016501629 B1 PH 12016501629B1 PH 12016501629 A PH12016501629 A PH 12016501629A PH 12016501629 B1 PH12016501629 B1 PH 12016501629B1
Authority
PH
Philippines
Prior art keywords
fusion proteins
uti fusion
same
uti
producing
Prior art date
Application number
PH1/2016/501629A
Other languages
English (en)
Other versions
PH12016501629A1 (en
Inventor
Aaron Chamberlain
Qiang Liu
Mathias Schmidt
Original Assignee
Takeda Gmbh
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh, Takeda Pharmaceuticals Co filed Critical Takeda Gmbh
Publication of PH12016501629A1 publication Critical patent/PH12016501629A1/en
Publication of PH12016501629B1 publication Critical patent/PH12016501629B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
PH1/2016/501629A 2014-02-24 2015-02-23 Uti fusion proteins PH12016501629B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461943617P 2014-02-24 2014-02-24
PCT/US2015/017152 WO2015127391A1 (en) 2014-02-24 2015-02-23 Uti fusion proteins

Publications (2)

Publication Number Publication Date
PH12016501629A1 PH12016501629A1 (en) 2017-02-06
PH12016501629B1 true PH12016501629B1 (en) 2023-10-20

Family

ID=52629709

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2016/501629A PH12016501629B1 (en) 2014-02-24 2015-02-23 Uti fusion proteins

Country Status (38)

Country Link
US (4) US9856310B2 (cg-RX-API-DMAC7.html)
EP (2) EP3443978A1 (cg-RX-API-DMAC7.html)
JP (4) JP6574431B2 (cg-RX-API-DMAC7.html)
KR (3) KR102461210B1 (cg-RX-API-DMAC7.html)
CN (2) CN106232135B (cg-RX-API-DMAC7.html)
AR (1) AR101597A1 (cg-RX-API-DMAC7.html)
AU (4) AU2015218704B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016019390B1 (cg-RX-API-DMAC7.html)
CA (2) CA2939639C (cg-RX-API-DMAC7.html)
CL (1) CL2016002136A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160444A (cg-RX-API-DMAC7.html)
CY (1) CY1120997T1 (cg-RX-API-DMAC7.html)
DK (1) DK3110434T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2016000202A (cg-RX-API-DMAC7.html)
EA (2) EA202091567A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP16076535A (cg-RX-API-DMAC7.html)
ES (1) ES2700149T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20196970B (cg-RX-API-DMAC7.html)
HR (1) HRP20182029T1 (cg-RX-API-DMAC7.html)
IL (1) IL247321B (cg-RX-API-DMAC7.html)
JO (1) JO3729B1 (cg-RX-API-DMAC7.html)
LT (1) LT3110434T (cg-RX-API-DMAC7.html)
MA (1) MA39347B2 (cg-RX-API-DMAC7.html)
MX (4) MX384070B (cg-RX-API-DMAC7.html)
MY (1) MY178774A (cg-RX-API-DMAC7.html)
NZ (3) NZ724196A (cg-RX-API-DMAC7.html)
PE (1) PE20170257A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016501629B1 (cg-RX-API-DMAC7.html)
PL (1) PL3110434T3 (cg-RX-API-DMAC7.html)
PT (1) PT3110434T (cg-RX-API-DMAC7.html)
RS (1) RS58285B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201606691QA (cg-RX-API-DMAC7.html)
SI (1) SI3110434T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800674T1 (cg-RX-API-DMAC7.html)
TW (1) TWI694084B (cg-RX-API-DMAC7.html)
UA (1) UA118866C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015127391A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201606327B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20160444A (es) * 2014-02-24 2017-04-21 Takeda Gmbh Proteínas de fusión uti
PE20251181A1 (es) * 2017-06-07 2025-04-23 Spark Therapeutics Inc Agentes potenciadores para la transfeccion celular mejorada y/o la produccion del vector raav
WO2020106881A1 (en) * 2018-11-20 2020-05-28 Diamedica Inc. Modified ulinastatin polypeptides
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
BR112022017718A2 (pt) * 2020-03-05 2022-11-16 Diamedica Usa Inc Polipeptídeos de ulinastatina

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
EP0401508B1 (de) * 1989-05-13 1994-11-23 Bayer Ag Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
US5409895A (en) 1990-11-13 1995-04-25 Mochida Pharmaceutical Co., Ltd. Protease inhibitory polypeptides derived from urinary trypsin inhibitor and compositions thereof
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
TR199801794T2 (xx) 1996-03-11 2000-07-21 Bayer Corporation �nsan bikunini.
DE19725014A1 (de) 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
WO2005095457A2 (en) * 2004-03-30 2005-10-13 Glaxo Group Limited Immunoglobulins
BRPI0514259A (pt) * 2004-08-11 2008-06-03 Trubion Pharmaceuticals Inc proteìna de fusão de domìnio de ligação
CN103665168A (zh) * 2005-06-03 2014-03-26 持田制药株式会社 抗cd14抗体融合蛋白质
EP1981519B1 (en) 2005-12-29 2017-12-27 Dyax Corp. Protease inhibition
CA2737241C (en) * 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
CN102580085B (zh) * 2008-10-13 2013-09-18 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗脓毒症药物中的应用
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
JP2012525847A (ja) * 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
PT3053932T (pt) * 2010-02-19 2020-10-21 Xencor Inc Novas imunoadesinas ctla4-ig
SI2704737T1 (en) * 2011-04-29 2018-06-29 University Of Washington Therapeutic nuclease compositions and methods
US8619331B2 (en) 2011-07-19 2013-12-31 Xerox Corporation Simulated paper texture using clear toner and glossmark on texture-less stock
JP6138815B2 (ja) * 2011-12-01 2017-05-31 エーピー バイオサイエンシーズ， インコーポレイテッド 補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法
BR112014026162A2 (pt) * 2012-04-23 2017-10-03 Nrl Pharma Inc Proteína de fusão ou variante da mesma, molécula de ácido nucleico, vetor de expressão, célula hospedeira, animal não humano geneticamente modificado, planta geneticamente modificada, agente terapêutico para doenças melhoradas por lactoferrina, composição farmacêutica, e, método para preparar a proteína de fusão ou variante da mesma
CN103044554B (zh) 2012-05-14 2014-08-27 旭华（上海）生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
JP2013253079A (ja) * 2012-05-14 2013-12-19 Xuhua (Shanghai) Biological Research & Development Center Co Ltd 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用
CR20160444A (es) * 2014-02-24 2017-04-21 Takeda Gmbh Proteínas de fusión uti

Also Published As

Publication number Publication date
EP3110434B1 (en) 2018-09-19
ECSP16076535A (es) 2017-08-31
JO3729B1 (ar) 2021-01-31
CN106232135B (zh) 2019-12-10
KR102722304B1 (ko) 2024-10-28
IL247321B (en) 2020-06-30
AU2015218704B2 (en) 2019-05-02
US20160362475A1 (en) 2016-12-15
PE20170257A1 (es) 2017-03-30
JP6574431B2 (ja) 2019-09-11
BR112016019390A2 (pt) 2017-10-24
ZA201606327B (en) 2019-01-30
SG11201606691QA (en) 2016-09-29
CN106232135A (zh) 2016-12-14
MX2019013124A (es) 2020-08-31
BR112016019390B1 (pt) 2023-11-14
CA2939639C (en) 2023-01-24
US20180072795A1 (en) 2018-03-15
JP2023123763A (ja) 2023-09-05
SI3110434T1 (sl) 2019-02-28
PL3110434T3 (pl) 2019-01-31
CA2939639A1 (en) 2015-08-27
HRP20182029T1 (hr) 2019-02-08
MX384070B (es) 2025-03-14
JP6938565B2 (ja) 2021-09-22
KR20240155987A (ko) 2024-10-29
CN110092837B (zh) 2024-01-02
AU2021225156A1 (en) 2021-09-30
UA118866C2 (uk) 2019-03-25
CN110092837A (zh) 2019-08-06
MX2016010950A (es) 2017-04-25
US10351618B2 (en) 2019-07-16
US20220127334A1 (en) 2022-04-28
CY1120997T1 (el) 2019-12-11
WO2015127391A1 (en) 2015-08-27
AU2019204448B2 (en) 2021-06-10
DOP2016000202A (es) 2016-12-15
CR20160444A (es) 2017-04-21
EA037256B1 (ru) 2021-02-26
AU2021225156B2 (en) 2022-11-24
KR20160141718A (ko) 2016-12-09
SG10201708400QA (en) 2017-11-29
MA39347A1 (fr) 2018-06-29
KR102461210B1 (ko) 2022-10-31
GEP20196970B (en) 2019-04-25
MX2024000004A (es) 2024-02-20
IL247321A0 (en) 2016-09-29
KR20220151005A (ko) 2022-11-11
MY178774A (en) 2020-10-20
US20200040062A1 (en) 2020-02-06
EP3443978A1 (en) 2019-02-20
CL2016002136A1 (es) 2017-08-11
SMT201800674T1 (it) 2019-01-11
CA3178241A1 (en) 2015-08-27
JP2017512058A (ja) 2017-05-18
EA201691702A1 (ru) 2017-01-30
AU2023200875A1 (en) 2023-04-27
ES2700149T3 (es) 2019-02-14
EA202091567A1 (ru) 2021-07-30
TWI694084B (zh) 2020-05-21
LT3110434T (lt) 2018-12-27
TW201630931A (zh) 2016-09-01
AR101597A1 (es) 2016-12-28
US9856310B2 (en) 2018-01-02
DK3110434T3 (en) 2019-01-14
RS58285B1 (sr) 2019-03-29
PH12016501629A1 (en) 2017-02-06
AU2019204448A1 (en) 2019-07-11
NZ760789A (en) 2023-03-31
NZ760008A (en) 2023-03-31
PT3110434T (pt) 2018-12-19
JP2019187427A (ja) 2019-10-31
JP2022002513A (ja) 2022-01-11
EP3110434A1 (en) 2017-01-04
NZ724196A (en) 2022-01-28
MA39347B2 (fr) 2020-05-29
AU2015218704A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
ZA201707749B (en) Compounds targeting proteins, compositions, methods, and uses thereof
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12017500858A1 (en) Mocrocyclic peptides useful as immunomodulators
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MY191581A (en) Anti-pd-1 antibodies
SG10201803042PA (en) Anti-tim-3 antibodies
MY193661A (en) Anti-tim3 antibodies and methods of use
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MY176855A (en) Anti-jagged1 antibodies and methods of use
EP3298170A4 (en) Methods for generating circular dna from circular rna
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
CY1120997T1 (el) Πρωτεϊνες συντηξης uti
MX2020012893A (es) Formulaciones de proteinas.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
SG11201704625UA (en) Novel methods for enzyme mediated polypeptide conjugation using sortase
EP3269725A4 (en) Method for producing protein composition, and protein composition
UY36277A (es) Proteínas de fusión uti
NZ744340A (en) Anti-jagged1 antibodies and methods of use
EP3221449A4 (en) Process for refolding recombinant chymotrypsin